Integrating Hepatitis C and Substance Use Disorder Treatment (1.5 CME)
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:
|This 90-minute workshop will use didactic instruction and small group discussion to provide models for integration of concurrent treatment of hepatitis C virus (HCV) and substance use disorder (SUD). Globally, HCV is a leading cause of liver-related mortality. In the United States, HCV is the most common blood-borne pathogen and deaths from HCV exceed those associated with HIV infection. Injection drug use is the foremost risk factor for HCV acquisition in the United States and estimates of the prevalence of HCV infection among persons who inject drugs (PWID) ranges between 40 �" 80%, dependent upon the sample. With the advent of direct-acting antiviral (DAA) regimens for treatment of HCV infection, it is now a curable disease. Despite recommendations for treatment of HCV in PWID, regardless of their current drug use status, treatment initiation in this population remains low. Using the opioid epidemic as a framework for the discussion, the presenters will discuss their own experiences in integrating HCV and SUD treatment, within 3 different modalities: 1) integration of HCV treatment into an opioid treatment program 2) integration of office-based buprenorphine treatment (OBOT) into a HCV clinic and 3) integration of HCV treatment and OBOT into a primary care practice. The session will start with a brief overview of HCV epidemiology, screening and treatment, followed by description of the 3 different models of integration. The group will then break into three/four smaller groups for facilitated discussion to allow participants to brainstorm how to best integrate HCV and SUD treatment in their own clinical settings. In each small group, a presenter will facilitate the dialogue ensuring discussion of key points for consideration. At the end of the session, the large group will reconvene. One participant from each small group will report on the content of their discussion providing an opportunity for cross-learning amongst workshop participants. Presenters will provide a brief summary emphasizing the key concepts for the workshop and answer any outstanding questions on integration of HCV and SUD treatment. Proposed Timeline (in minutes): 0:00 �" 0:15 Introduction and Overview of HCV epidemiology, screening, and treatment 0:15 �" 1:00 Discussion of 3 HCV/SUD treatment integration models 1:00 �" 1:15 Small Group Case Discussions 1:15 �" 1:20 Large Group Discussion of Cases 1:20 �" 1:30 Questions and Answers/Session Evaluation|
|1.) Discuss HCV epidemiology, screening and treatment particularly as it pertains to persons who inject drugs.|
|2.) Describe at least 3 different models for integration of HCV and SUD treatment.|
|3.) Identify ways to integrate HCV and SUD into their own clinical practice setting.|
MD, MS, FASAM, FACP
Anika Alvanzo, MD, MS is an Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine where she is also the Medical Director of the Johns Hopkins Hospital Substance Use Disorders Consultation Service (SUDS). Dr. Alvanzo is a graduate of the George Washington University School of Medicine and Health Sciences and holds a master's degree in biostatistics from Virginia Commonwealth University. She is board certified in both Internal Medicine and Addiction Medicine. As the Director of the SUDS, Dr. Alvanzo oversees a multidisciplinary consultation service that performs brief behavioral interventions and counseling for hospitalized patients, facilitates linkage to hospital and community-based alcohol and drug treatment programs, provides guidance on the clinical management of substance withdrawal syndromes, and educates patients, families, healthcare professionals and the community to prevent, identify, and treat persons living with addiction. Dr. Alvanzo is also the Director of the Substance Use Disorders Rotation for the Johns Hopkins Medicine-Pediatrics Urban Health and Urban Health Primary Care Residency track programs. Her research interests include gender and race/ethnicity differences in the risk for substance use disorders, integration of technology for screening, brief intervention and referral to treatment in diverse settings and the association between psychological trauma, traumatic stress, and substance use. In particular, she is interested in the mechanisms by which histories of physical and/or sexual violence confer increased risk for substance use disorders and in the development of interventions for co-occurring traumatic stress and substance misuse in women.
MD, MPH, DFASAM
Medical Director at Institutes for Behavior Resources, Inc.
Oluwaseun Falade-Nwulia, MBBS, MPH, is an Assistant Professor in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine.She focuses her clinical pursuits on care of HIV and HCV infected patients and educating clinicians and public health practitioners about STDs, HIV, and hepatitis. Her research focuses on understanding the distribution and impact of highly active antiretroviral therapy on hepatitis B and C outcomes, and on improving HIV and hepatitis C (HCV) testing and access to care in medically underserved communities.
|Dr. Megan Buresh is an Assistant Professor of Medicine and Epidemiology at the Johns Hopkins University School of Medicine. She is board certified in internal medicine and addiction medicine and certified as AAHIVM HIV Specialist. She received a Bachelor of Arts in Biochemical Sciences from Harvard University (magna cum laude with highest honors in field), completed medical school at Johns Hopkins University School of Medicine and residency at Brigham and Women’s Hospital. She is the Secretary of the Maryland-DC ASAM Chapter. She is medical director of the Johns Hopkins Bayview Inpatient Addiction Consult Service. She also provides integrated buprenorphine treatment as part of her outpatient primary care practice. She is lead physician for BHLI PCARE, a mobile buprenorphine clinic for patients being released from Baltimore City Jail. Her research interests include public health and addiction, developing and evaluating models to expand office-based opioid treatment, and improving linkages between clinical addiction treatment and community organizations. She is a co-investigator with the ALIVE study at the Johns Hopkins Bloomberg School of Public Health, where she is studying risk factors for opiate overdose and access to naloxone among persons who inject drugs.|
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.